儿科异常性心肌病:病因学的挑战和需要向治疗的需求
Meaunique Pollock1, William H Frishman1,2
1New York Medical College, Valhalla, NY.
Cardiology in review
|December 10, 2025
概括
诊断儿科异形性心肌病是具有挑战性的,因为未知原因,复杂的治疗. 开发有针对性的疗法需要专门针对儿科的研究和精准医学方法,以获得更好的结果.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 遗传学 遗传学 是一个
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 儿童的异常心肌病是一种严重的疾病,死亡率高.
- 病因学是复杂的,通常涉及遗传突变或代谢问题,但明确的原因仍然难以捉摸.
- 目前的诊断和治疗策略有限,影响患者的治疗结果.
研究的目的:
- 审查识别儿科异常心肌病的病因学的局限性.
- 检查这些诊断挑战如何影响针对性儿科治疗的发展.
- 突出需要改进的研究和治疗策略.
主要方法:
- 进行了全面的文献审查.
- 分析包括临床试验,队列研究和专家共识陈述.
- 专注于儿科心肌病病因,治疗和结果.
主要成果:
- 许多儿科心肌病治疗方法是从成人研究中改编的,有效性有限.
- 缺乏标准化分类,药理学证据不足,儿科试验少,导致预后不佳.
- 目前的通用治疗实践产生了低于最佳的结果.
结论:
- 推进儿科心肌病治疗需要精准医学框架和强大的基因型-表型数据库.
- 开发专门针对儿科的临床试验至关重要.
- 增加对儿科研究和有针对性的策略的关注对于改善生存和结果至关重要.
更多相关视频
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
4.1K
08:37Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.
Published on: March 3, 2021
4.9K
相关概念视频
Cardiomyopathy V: Interprofessional Care
313
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313
Cardiomyopathy II: Dilated Cardiomyopathy
436
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
436
Cardiomyopathy I: Introduction and Classification
479
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
479
Cardiomyopathy III: Hypertrophic Cardiomyopathy
362
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
362
Cardiomyopathy IV: Restrictive Cardiomyopathy
426
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
426
Pharmacokinetics in Pediatric Patients: Drug Metabolism
174
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
174
